Eledon Pharmaceuticals (ELDN) Cash from Investing Activities (2013 - 2026)

Eledon Pharmaceuticals has reported Cash from Investing Activities for 9 years, with the latest figure at $6.0 million in Q1 2026.

• For the quarter ending Q1 2026, Cash from Investing Activities rose 53.03% year-over-year to $6.0 million; the trailing twelve-month figure through Mar 2026 stood at $12.9 million (up 116.87% YoY), and the FY2025 full-year result was $10.8 million, up 115.35% from the prior year.
• Cash from Investing Activities for Q1 2026 stood at $6.0 million, up from -$20.5 million in the prior quarter.
• The five-year high for Cash from Investing Activities was $15.0 million in Q2 2025, with the low at -$47.4 million in Q4 2024.
• Historically, Cash from Investing Activities has averaged -$6.2 million across 4 years, with a median of $3.9 million in 2025.
• Annual changes were most pronounced in 2024 — Cash from Investing Activities sank 570.25% — and 2025, when it soared 196.9%.
• Eledon Pharmaceuticals' Cash from Investing Activities stood at $10.1 million in 2023, then slumped by 570.25% to -$47.4 million in 2024, then surged by 56.81% to -$20.5 million in 2025, then jumped by 129.11% to $6.0 million in 2026.
• The last three Cash from Investing Activities figures came in at $6.0 million (Q1 2026), -$20.5 million (Q4 2025), and $12.4 million (Q3 2025), per Business Quant data.